Targeting alpha-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations, Lancet Neurol, 2015. ,
Ageing and neuronal vulnerability, Nat Rev Neurol, vol.7, issue.4, pp.278-294, 2006. ,
Ageing as a primary risk factor for Parkinson's disease: evidence from studies of non-human primates, Nat Rev Neurol, vol.12, issue.6, pp.359-366, 2011. ,
Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease, Trends Neurosci, vol.30, issue.5, pp.244-250, 2007. ,
Alpha-synuclein in Lewy bodies, Nature, vol.388, issue.6645, pp.839-840, 1997. ,
Mutation in the alphasynuclein gene identified in families with Parkinson's disease, Science, vol.276, issue.5321, pp.2045-2047, 1997. ,
Genetic mouse models of Parkinson's disease The state of the art, Prog Brain Res, vol.184, issue.10, p.84004, 2010. ,
Animal models of Parkinson's disease: limits and relevance to neuroprotection studies, Mov Disord: Off J Mov Dis Soc, vol.28, issue.1, pp.61-70, 2013. ,
vector-mediated overexpression of alpha-synuclein in mouse substantia nigra induces protein aggregation and progressive dose-dependent neurodegeneration, Mol Neurodegener, vol.8, p.44, 2013. ,
Longitudinal follow-up and characterization of a robust rat model for Parkinson's disease based on overexpression of alpha-synuclein with adeno-associated viral vectors, Neurobiol Aging, vol.36, issue.3, pp.1543-1558, 2015. ,
Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield, Gene Ther, vol.6, issue.6, pp.973-985, 1999. ,
Universal real-time PCR for the detection and quantification of adenoassociated virus serotype 2-derived inverted terminal repeat sequences, Hum Gene Ther Methods, vol.23, issue.1, pp.18-28, 2012. ,
Levodopa gains psychostimulant-like properties after nigral dopaminergic loss, Ann Neurol, vol.74, issue.1, pp.140-144, 2013. ,
URL : https://hal.archives-ouvertes.fr/hal-01153692
Versatile robotic interface to evaluate, enable and train locomotion and balance after neuromotor disorders, Nat Med, vol.18, issue.7, pp.1142-1147, 2012. ,
Reinforcing properties of Pramipexole in normal and parkinsonian rats, Neurobiol Dis, vol.49, pp.79-86, 2013. ,
URL : https://hal.archives-ouvertes.fr/hal-01153677
Selective Inactivation of Striatal FosB/DeltaFosB-Expressing Neurons Alleviates L-Dopa-Induced Dyskinesia, Biol Psychiatry, 2014. ,
Restoring voluntary control of locomotion after paralyzing spinal cord injury, Science, vol.336, issue.6085, pp.1182-1185, 2012. ,
Dopamine control of pyramidal neuron activity in the primary motor cortex via D2 receptors, Frontiers Neural Circuits, vol.8, p.13, 2014. ,
Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of alpha-synuclein in midbrain dopamine neurons, Neurobiol Dis, vol.45, issue.3, pp.939-953, 2012. ,
Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system, J Neurosci, vol.22, issue.7, pp.2780-2791, 2002. ,
) alpha-Synuclein is phosphorylated in synucleinopathy lesions, Nat Cell Biol, vol.4, issue.2, pp.160-164, 2002. ,
Differential strain susceptibility following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration acts in an autosomal dominant fashion: quantitative analysis in seven strains of Mus musculus, Brain Res, vol.828, issue.1-2, pp.91-103, 1999. ,
Muscle spindle feedback directs locomotor recovery and circuit reorganization after spinal cord injury, Cell, vol.159, issue.7, pp.1626-1639, 2014. ,
A novel murine model of aging, Senescence-Accelerated Mouse (SAM), Arch Gerontol Geriatr, vol.19, issue.2, pp.185-192, 1994. ,
Targeting ?-synuclein for treating Parkinson's disease: mechanistic and therapeutic considerations, Lancet Neurology, vol.2, issue.1, pp.141-151, 2007. ,
Threonine 53 in alpha-synuclein is conserved in long-living non-primate animals, Biochem Biophys Res Commun, vol.387, issue.3, pp.602-605, 2009. ,
alpha-Synuclein A53T substitution associated with Parkinson disease also marks the divergence of Old World and New World primates, Genomics, vol.83, issue.4, pp.739-742, 2004. ,
Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease, J Neurosci, vol.21, issue.17, pp.6853-6861, 2001. ,
Compensatory mechanisms in experimental and human parkinsonism: towards a dynamic approach, Prog Neurobiol, vol.55, issue.2, pp.93-116, 1998. ,
Long-term consequences of human alpha-synuclein overexpression in the primate ventral midbrain, Brain :J Neuro, vol.130, pp.799-815, 2007. ,
) alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease, Proc Natl Acad Sci U S A, vol.99, issue.16, pp.10813-10818, 2002. ,
Phosphorylation at Ser-129 but not the phosphomimics S129E/D inhibits the fibrillation of alpha-synuclein, J Biol Chem, vol.283, issue.24, pp.16895-16905, 2008. ,
Ser129 phosphorylation of endogenous alpha-synuclein induced by overexpression of polo-like kinases 2 and 3 in nigral dopamine neurons is not detrimental to their survival and function, Neurobiol Dis, vol.78, pp.100-114, 2015. ,
) alpha-synuclein phosphorylation and truncation are normal events in the adult human brain, Neuroscience, vol.200, pp.106-119, 2012. ,
The relationships between aging, monoamine oxidase, striatal dopamine and the effects of MPTP in C57BL/6 mice: a critical reassessment, Brain Res, vol.572, issue.1-2, pp.224-231, 1992. ,
Age-related effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment of common marmosets, Eur J Pharmacol, vol.230, issue.2, pp.177-185, 1993. ,
Increased susceptibility to MPTP toxicity in middle-aged rhesus monkeys, Neurobiol Aging, vol.16, issue.6, pp.931-937, 1995. ,
Molecular and neurochemical mechanisms in PD pathogenesis, Neurotox Res, vol.16, issue.3, pp.271-279, 2009. ,
Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease, Nature, vol.334, issue.6180, pp.345-348, 1988. ,
Does neuromelanin contribute to the vulnerability of catecholaminergic neurons in monkeys intoxicated with MPTP?, Neuroscience, vol.56, issue.2, pp.499-511, 1993. ,
Progressive dopamine neuron loss in Parkinson's disease: the multiple hit hypothesis, Cell Transplant, vol.15, issue.3, pp.239-250, 2006. ,